PCA
CHRS icon

Pallas Capital Advisors’s Coherus Oncology CHRS Stock Holding History

Pallas Capital Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4K Sell
11,014
-531
-5% -$867 ﹤0.01% 1019
2026
Q1 		$19.5K Buy
+11,545
New +$20.5K ﹤0.01% 853
2025
Q3 		– Sell
-13,696
Closed -$10K – 891
2025
Q2 		$10K Buy
13,696
+938
+7% +$810 ﹤0.01% 855
2025
Q1 		$10.3K Buy
+12,758
New +$14.7K ﹤0.01% 761

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Pallas Capital Advisors's CHRS Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Coherus Oncology (CHRS) stake by 4.6% in Q2 2026, selling an estimated $867 and leaving 11,014 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1019.

Pallas Capital Advisors first reported a position in CHRS in Q1 2025 and has held it in 4 quarters since. The position peaked at $19.5K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Pallas Capital Advisors held 11,014 shares of Coherus Oncology worth $15.4K as of Q2 2026.
  • Pallas Capital Advisors sold 531 Coherus Oncology shares in Q2 2026, an estimated $867.
  • Coherus Oncology made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #1019 holding.
  • Pallas Capital Advisors first reported a position in Coherus Oncology in Q1 2025 and has held it in 4 quarters since.
  • Pallas Capital Advisors's Coherus Oncology position peaked at $19.5K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.